Joo Mee Kim’s practice centers on providing a broad range of IP-related legal advocacy, counsel, and representation to diverse clients, including clients from her native Korea. With extensive experience as a practicing attorney in both countries, Joo Mee is uniquely positioned to assist Korean companies in numerous industries navigate the challenges of the United States legal system.

Her clients’ industries include the life sciences, pharmaceuticals, chemicals, cosmetics, and electronics (including handsets, display devices, and home appliances) arenas, as well as materials for the IT and semiconductor industries. Her work on their behalf is equally broad and diverse, including both patent prosecution and litigation, Hatch-Waxman litigation, and post-grant work and advisory services such as rendering legal opinions and patent portfolio management and evaluation. Her notable representations include, among others, Hatch-Waxman litigations for Mylan Pharmaceuticals, patent litigations and arbitrations for LG Electronics, Rexall, Inc., and Nature’s Bounty, and post-grant review cases for Celltrion, LG Chem, LTD., LG Electronics, Inc., and AmorePacific.

Although every case is different, Joo Mee is responsible for assembling and managing a team of attorneys who are best qualified for the case, as well as personally helping with the development of a case strategy and detailed arguments. At every stage, she is responsible for communicating with clients to ensure they are fully informed.

A native of Seoul, Joo Mee was originally trained and licensed as a pharmacist in Korea. This professional experience gave her a strong knowledge base for working with pharmaceutical and life sciences clients as an attorney. She then studied and successfully sat for the Korean patent bar examination and as a Korean patent attorney, she began representing major pharmaceutical and chemical clients, including AstraZeneca, MSD, and Nissan Chemical, in patent infringement cases. She moved to the United States in 1998, passed the bar exams, and began representing clients in a general law firm, providing primarily services related to patent prosecution and freedom-to-operate, non-infringement, and invalidity opinions in the areas of genetic engineering, molecular biology, monoclonal antibodies, cancer treatments, and protein production in plants.

Honors & Recognitions

Washington, D.C. Super Lawyers (2014-2024)
Ranked for Intellectual Property Litigation and Intellectual Property


Speaking Engagements

"The Norvasc CAFC Decision and Thereafter,” presented at the Symposium sponsored by Daily Pharm, June 21, 2007, Korea.

"Obviousness after KSR," presented at the Symposium sponsored by Daily Pharm, June 21, 2007, Seoul, Korea.

“U.S. Generic Market,” -- taught in the program entitled “Strategies for Exporting Pharmaceutical Products to the U.S. Market,” sponsored by Korea Health Industry Development Institute and Pharmaceutical Industries, October 12, 2007

"How the 2003 Hatch-Waxman Reform Has Changed NDA/Generic Practice in the U.S,” presented at the Symposium sponsored by Darae Law & Patent Firm, November 9, 2005.


"Patent Law Perspective on the Report of the Federal Trade Commission on Balancing Competition and Patent Law and Policy" written by E. Anthony Figg, C. Nichole Gifford and Joo Mee Kim, presented to the ABA Section of Antitrust Law, May 2004.

Community & Professional

Third President of the Korean-American Intellectual Property Lawyers Association ("KAIPLA")


L.L.M., Intellectual Property, The George Washington University Law School

M.S., International Law, Sung Kyun Kwan University

B.S., Pharmacy, Seoul National University


  • Korean

Bar & Court Admissions

Bar Admissions

  • District of Columbia
  • New York
Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.